MAINTREG

FOXP3 expressing regulatory CD4+ T (Treg) cells are instrumental for the maintenance of self-tolerance. Treg cell therapy has a promising potential for the treatment of autoimmune diseases or for the induction of operational tolerance in solid organ transplantation. However human Treg cells are unstable in term of FOXP3 expression, specific epigenetics and suppressive function in vitro and in vivo. By next gen methods combining surface markers and transcriptome simultaneous translationnal analysis of Treg cells at the single cell level, in various settings including IPEX disease our ongloing phase I Treg cell therapy trial in liver and kidney transplantion, in vitro developping CAR-Treg cells and thymic Treg cells, we can determine targetable factors that are responsible for this instability and therefore aim at proposing fully optimized GMP expansion protocol for Treg cell expansion for cell therapy.